UnitedHealth: Solid Quarter, Maintaining 2020 Outlook

Results and outlook for the wide-moat firm bode well for the discounted managed-care industry, and shares appear moderately undervalued.

Securities In This Article
UnitedHealth Group Inc
(UNH)

Narrow-moat UnitedHealth Group UNH reported solid first-quarter operating results, and despite challenges presented by the COVID-19 crisis, particularly surrounding its own care provider operations, the company maintained its outlook for 2020. In general, UnitedHealth's results and outlook bode well for the discounted managed-care industry, and UnitedHealth shares appear moderately undervalued.

For the quarter, UnitedHealth beat Capital IQ consensus on both the top and bottom lines, and management noted that the COVID-19 crisis did not have a material impact on those results, given how late in the quarter that situation developed in the United States. Perhaps even more importantly, management also reiterated its guidance for 2020. The company continues to expect adjusted earnings per share of $16.25-$16.55 for the year, and our EPS projection remains within that range. In general, there appear to be several offsetting factors that could buoy UnitedHealth's near-term results. Also, management noted that risk-based (rather than fee-for-service) arrangements account for about two thirds of its service provider revenue, meaning about two thirds of those operations benefit from reduced care costs.

In addition to these financial disclosures, UnitedHealth also described a number of COVID-19 responses that suggest the immediate risks surrounding the health crisis are probably manageable for the organization and the industry as a whole. Investors have appeared concerned about medical costs that could rise and push down profits in a severe COVID-19 scenario. However, we suspect the inflated COVID-19 patient costs could be offset by reduced volume in other services, like routine care and elective procedures. For example, UnitedHealth's decision to assume all member costs associated with COVID-19 along with its plan to provide $2 billion of advanced payments to care providers, among other actions, suggest that overall medical costs will likely be well under control in 2020.

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

More in Stocks

About the Author

Julie Utterback, CFA

Senior Equity Analyst
More from Author

Julie Utterback, CFA, is a senior equity analyst, AM Healthcare, for Morningstar*. She focuses on medical technology and service companies. She covers managed care organizations including UnitedHealth, service providers like HCA, medical suppliers such as Baxter, and life sciences companies like Danaher. She is also the chairperson of the equity research team’s capital allocation methodology.

Before joining Morningstar in 2005, Utterback was an equity analyst at State Farm Insurance for several years. Utterback joined Morningstar in 2005 as an equity analyst in the healthcare industry, and initially she primarily covered medical technology companies, including orthopedic device, medical equipment, and cardiac device firms. In 2010, she joined Morningstar's credit research team, initiating coverage of the entire healthcare industry and generally helping the organization expand and maintain its credit coverage across many industries. She held that senior credit analyst role until April 2019, when she returned to the equity team to cover medical technology and service companies.

Utterback holds a bachelor's degree in finance from the University of Illinois Urbana-Champaign’s Gies College of Business. She also holds the Chartered Financial Analyst® designation.

* Morningstar Research Services LLC (“Morningstar”) is a wholly owned subsidiary of Morningstar, Inc

Sponsor Center